Detalhe da pesquisa
1.
Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial.
BMC Neurol
; 21(1): 459, 2021 Nov 23.
Artigo
Inglês
| MEDLINE | ID: mdl-34814867
2.
Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
J Neurol Neurosurg Psychiatry
; 87(1): 106-12, 2016 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-25669746
3.
Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial.
Alzheimer Dis Assoc Disord
; 30(1): 1-7, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-26885819
4.
A two-level multimodality imaging Bayesian network approach for classification of partial epilepsy: preliminary data.
Neuroimage
; 71: 224-32, 2013 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23353601
5.
Validation of 3- and 5-point severity scales to assess ARIA-E.
Alzheimers Dement (Amst)
; 15(4): e12503, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-38026755
6.
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease.
Alzheimers Dement (N Y)
; 9(1): e12377, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36949897
7.
Development, initial validation, and application of a visual read method for [18F]MK-6240 tau PET.
Alzheimers Dement (N Y)
; 9(1): e12372, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36873926
8.
Comparing ARIA-E severity scales and effects of treatment management thresholds.
Alzheimers Dement (Amst)
; 14(1): e12376, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36474747
9.
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
JAMA Neurol
; 79(1): 13-21, 2022 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34807243
10.
Reviewing CT Scout Images: Observations of an Expert Witness.
AJR Am J Roentgenol
; 206(2): W49, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26797385
11.
Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.
Alzheimers Dement
; 7(4): 396-401, 2011 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-21784350
12.
Involvement of the thalamocortical network in TLE with and without mesiotemporal sclerosis.
Epilepsia
; 51(8): 1436-45, 2010 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-20002143
13.
Age-related gray matter shrinkage in a treatment naïve actively drinking alcohol-dependent sample.
Alcohol Clin Exp Res
; 34(1): 175-82, 2010 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-19860794
14.
Magnetic resonance imaging quality and volumes of brain structures from live and postmortem imaging of California sea lions with clinical signs of domoic acid toxicosis.
Dis Aquat Organ
; 91(3): 243-56, 2010 Sep 17.
Artigo
Inglês
| MEDLINE | ID: mdl-21133324
15.
Intra-lacrimal gland cavernous hemangioma.
Orbit
; 29(6): 354-6, 2010 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-21158578
17.
Subfield atrophy pattern in temporal lobe epilepsy with and without mesial sclerosis detected by high-resolution MRI at 4 Tesla: preliminary results.
Epilepsia
; 50(6): 1474-83, 2009 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-19400880
18.
Parietal gray matter volume loss is related to spatial processing deficits in long-term abstinent alcoholic men.
Alcohol Clin Exp Res
; 33(10): 1806-14, 2009 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-19645730
19.
Increased white matter signal hyperintensities in long-term abstinent alcoholics compared with nonalcoholic controls.
Alcohol Clin Exp Res
; 33(1): 70-8, 2009 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-18976350
20.
Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease.
Alzheimers Dement (Amst)
; 2: 75-85, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-27239538